Dynamic changes in serum IL-6, TNF-, and β₂-microglobulin as early predictors of post-treatment relapse in lymphoma: a prospective cohort study.
[BACKGROUND] Early identification of relapse after first-line chemotherapy remains a major challenge in lymphoma management.
- OR 1.08
- HR 1.78
- 연구 설계 cohort study
APA
Ma Y, Song J, et al. (2026). Dynamic changes in serum IL-6, TNF-, and β₂-microglobulin as early predictors of post-treatment relapse in lymphoma: a prospective cohort study.. Frontiers in medicine, 13, 1750664. https://doi.org/10.3389/fmed.2026.1750664
MLA
Ma Y, et al.. "Dynamic changes in serum IL-6, TNF-, and β₂-microglobulin as early predictors of post-treatment relapse in lymphoma: a prospective cohort study.." Frontiers in medicine, vol. 13, 2026, pp. 1750664.
PMID
41767523
Abstract
[BACKGROUND] Early identification of relapse after first-line chemotherapy remains a major challenge in lymphoma management. Conventional imaging provides limited sensitivity for minimal residual disease and cannot detect early biochemical changes. This prospective cohort study evaluated whether dynamic changes in serum IL-6, TNF-, and β₂-microglobulin (β₂-MG) can serve as early predictors of relapse.
[METHODS] A total of 260 patients with pathologically confirmed lymphoma who completed standard chemotherapy were enrolled and followed longitudinally. Serum IL-6, TNF-, and β₂-MG were measured at T1 (end of chemotherapy), T2 (3 months post-treatment), and T3 (6 months post-treatment). Logistic regression, ROC analysis, Kaplan-Meier curves, and Cox proportional hazards models were used to assess predictive performance.
[RESULTS] During follow-up, 78 patients (30.0%) experienced relapse. All three biomarkers were significantly elevated in the relapse group at T1, and differences widened at T2 and T3. At T2, IL-6 (adjusted OR = 1.08), β₂-MG (adjusted OR = 1.38), and Ann Arbor stage and IPI score remained independent predictors. β₂-MG exhibited the strongest individual predictive value (AUC = 0.85), while the combined IL-6 + TNF- + β₂-MG model achieved superior discrimination (AUC = 0.91). Higher biomarker levels were associated with shorter relapse-free survival in Cox models, including high IL-6 (HR = 1.78), TNF- (HR = 1.52), and β₂-MG (HR = 2.06). Dynamic changes also showed strong predictive value, with ΔIL-6 (OR = 1.21) and Δβ₂-MG (OR = 1.34) indicating early biological progression before radiologic relapse becomes detectable.
[CONCLUSION] Longitudinal monitoring of IL-6, TNF-, and β₂-MG identifies early inflammatory trajectories linked to lymphoma relapse. IL-6 and β₂-MG at 3 months post-chemotherapy are independent and robust predictors, and a multi-marker model markedly enhances early-warning performance.
[METHODS] A total of 260 patients with pathologically confirmed lymphoma who completed standard chemotherapy were enrolled and followed longitudinally. Serum IL-6, TNF-, and β₂-MG were measured at T1 (end of chemotherapy), T2 (3 months post-treatment), and T3 (6 months post-treatment). Logistic regression, ROC analysis, Kaplan-Meier curves, and Cox proportional hazards models were used to assess predictive performance.
[RESULTS] During follow-up, 78 patients (30.0%) experienced relapse. All three biomarkers were significantly elevated in the relapse group at T1, and differences widened at T2 and T3. At T2, IL-6 (adjusted OR = 1.08), β₂-MG (adjusted OR = 1.38), and Ann Arbor stage and IPI score remained independent predictors. β₂-MG exhibited the strongest individual predictive value (AUC = 0.85), while the combined IL-6 + TNF- + β₂-MG model achieved superior discrimination (AUC = 0.91). Higher biomarker levels were associated with shorter relapse-free survival in Cox models, including high IL-6 (HR = 1.78), TNF- (HR = 1.52), and β₂-MG (HR = 2.06). Dynamic changes also showed strong predictive value, with ΔIL-6 (OR = 1.21) and Δβ₂-MG (OR = 1.34) indicating early biological progression before radiologic relapse becomes detectable.
[CONCLUSION] Longitudinal monitoring of IL-6, TNF-, and β₂-MG identifies early inflammatory trajectories linked to lymphoma relapse. IL-6 and β₂-MG at 3 months post-chemotherapy are independent and robust predictors, and a multi-marker model markedly enhances early-warning performance.
같은 제1저자의 인용 많은 논문 (5)
- A Streamlined Protocol for Developing a Clinicopathological Prediction Model for Patient Survival of Post-Resection of Pancreatic Cancer.
- Thermosensitive spray-gel oxaliplatin delivery system for antitumor efficacy and mechanistic study in a mouse subcutaneous xenograft model.
- LAP2α drives breast tumorigenesis by mitigating replication stress.
- Short-course high-dose cytarabine consolidation therapy before allogeneic hematopoietic stem cell transplantation improves 2-year relapse-free survival but not overall survival in patients with acute myeloid leukemia: a single-center retrospective study.
- ISX promotes tumor migration and invasion in lung cancer by upregulating COL1A1 .